{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T20:57:44Z","timestamp":1782507464661,"version":"3.54.5"},"reference-count":44,"publisher":"SAGE Publications","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAD"],"published-print":{"date-parts":[[2024,1,2]]},"abstract":"<jats:p>Background: Although the concordance between cerebrospinal fluid (CSF) Alzheimer\u2019s disease (AD) biomarkers and amyloid-PET findings is well known, there are no data regarding the concordance of amyloid-PET with inconclusive CSF values of amyloid-\u03b2 (A\u03b2)1\u00a0-\u00a042 and p-tau for the diagnosis of AD. Objective: To investigate the relationship between the amyloid-PET results with discordant AD biomarkers values in CSF (A\u03b21\u00a0-\u00a042+\/p-tau\u2013or A\u03b21\u00a0-\u00a042\u2013\/p-tau+). Methods: An observational retrospective study, including 62 patients with mild cognitive impairment (32\/62) or dementia (30\/62), suspicious of AD who had undergone a lumbar puncture to determine CSF AD biomarkers, and presented discordant values in CSF between A\u03b21\u00a0-\u00a042 and p-tau (A\u03b21\u00a0-\u00a042+\/p-tau\u2013or A\u03b21\u00a0-\u00a042\u2013\/p-tau+). All of them, underwent an amyloid-PET with 18F-Florbetaben. An extensive neuropsychological testing as part of their diagnostic process (MMSE and TMA-93), was performed, and it was also obtained the Global Deterioration Scale. Results: Comparing the discordant CSF results of each patient with the cerebral amyloid-PET results, we found that in the group with A\u03b21\u00a0-\u00a042+ and p-tau\u2013CSF values, the amyloid-PET was positive in 51.2% and negative in 48.8% of patients, while in the group with A\u03b21\u00a0-\u00a042\u2013and p-Tau+ CSF values, the amyloid-PET was positive in 52.6% of patients and negative in 47.4% of them. No significant association was found (p\u200a=\u200a0.951) between the results of amyloid-PET and the two divergent groups in CSF. Conclusions: No significant relationship was observed between the results of discordant AD biomarkers in CSF and the result of amyloid-PET. No trend in amyloid-PET results was observed in relation to CSF biomarker values.<\/jats:p>","DOI":"10.3233\/jad-230744","type":"journal-article","created":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T12:21:34Z","timestamp":1702988494000},"page":"447-458","source":"Crossref","is-referenced-by-count":3,"title":["Correlation Between Amyloid PET Imaging and Discordant Cerebrospinal Fluid Biomarkers Results in Patients with Suspected Alzheimer\u2019s Disease"],"prefix":"10.1177","volume":"97","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4945-8250","authenticated-orcid":false,"given":"Jose Antonio","family":"Lojo-Ram\u00edrez","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, Virgen del Roc\u00edo University Hospital, Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Guerra-G\u00f3mez","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Virgen del Roc\u00edo University Hospital, Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alba Marta","family":"Mar\u00edn-Caba\u00f1as","sequence":"additional","affiliation":[{"name":"Memory Unit, Department of Neurology, Virgen del Roc\u00edo University Hospital, Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Fern\u00e1ndez-Rodr\u00edguez","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Virgen del Roc\u00edo University Hospital, Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Bernal S\u00e1nchez-Arjona","sequence":"additional","affiliation":[{"name":"Memory Unit, Department of Neurology, Virgen del Roc\u00edo University Hospital, Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Franco-Mac\u00edas","sequence":"additional","affiliation":[{"name":"Memory Unit, Department of Neurology, Virgen del Roc\u00edo University Hospital, Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Garc\u00eda-Sol\u00eds","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Virgen del Roc\u00edo University Hospital, Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"key":"10.3233\/JAD-230744_ref1","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1474-4422(09)70299-6","article-title":"Hypothetical model of dynamic biomarkers of the Alzheimer\u2019s pathological cascade","volume":"9","author":"Jack","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-230744_ref2","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","article-title":"Toward defining the preclinical stages of Alzheimer\u2019s disease: Recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"Sperling","year":"2011","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-230744_ref3","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s00259-019-04536-9","article-title":"The A\/T\/N model applied through imaging biomarkers in a memory clinic","volume":"47","author":"Dodich","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.3233\/JAD-230744_ref4","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S1474-4422(14)70090-0","article-title":"Advancing research diagnostic criteria for Alzheimer\u2019s disease: The IWG-2 criteria","volume":"13","author":"Dubois","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-230744_ref5","doi-asserted-by":"crossref","first-page":"625","DOI":"10.3233\/JAD-160366","article-title":"Cerebrospinal fluid biomarkers for the differential diagnosis between Alzheimer\u2019s disease and frontotemporal lobar degeneration: Systematic review, HSROC analysis, and confounding factors","volume":"55","author":"Rivero-Santana","year":"2017","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-230744_ref6","doi-asserted-by":"crossref","first-page":"525","DOI":"10.3233\/JAD-141725","article-title":"Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer\u2019s disease from other dementias and healthy controls in the OPTIMA cohort","volume":"44","author":"Seeburger","year":"2015","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-230744_ref7","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA research framework: Toward a biological definition of Alzheimer\u2019s disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-230744_ref8","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer\u2019s disease: Recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-230744_ref9","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1001\/jama.2015.4669","article-title":"Prevalence of amyloid PET positivity in dementia syndromes: A meta-analysis","volume":"313","author":"Ossenkoppele","year":"2015","journal-title":"JAMA"},{"key":"10.3233\/JAD-230744_ref10","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13195-022-00967-z","article-title":"The A\u03b21\u201342\/A\u03b21\u201340 ratio in CSF is more strongly associated to tau markers and clinical progression than A\u03b21\u201342 alone","volume":"14","author":"Delaby","year":"2022","journal-title":"Alzheimers Res Therapy"},{"key":"10.3233\/JAD-230744_ref11","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jalz.2012.11.003","article-title":"Global standardization measurement of cerebral spinal fluid for Alzheimer\u2019s disease: An update from the Alzheimer\u2019s Association Global Biomarkers Consortium","volume":"9","author":"Carrillo","year":"2013","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-230744_ref12","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3233\/JAD-2012-120361","article-title":"Risk of Alzheimer\u2019s disease biological misdiagnosis linked to cerebrospinal collection tubes","volume":"31","author":"Perret-Liaudet","year":"2012","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-230744_ref13","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jalz.2013.01.010","article-title":"CSF biomarker variability in the Alzheimer\u2019s Association quality control program","volume":"9","author":"Mattsson","year":"2013","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-230744_ref14","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S1474-4422(12)70142-4","article-title":"Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-\u03b2 plaques: A prospective cohort study","volume":"11","author":"Clark","year":"2012","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-230744_ref15","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.jalz.2015.02.004","article-title":"Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer\u2019s disease: Phase 3 study","volume":"11","author":"Sabri","year":"2015","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-230744_ref16","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/S1474-4422(11)70077-1","article-title":"Cerebral amyloid-\u03b2 PET with florbetaben (18F) in patients with Alzheimer\u2019s disease and healthy controls: A multicentre phase 2 diagnostic study","volume":"10","author":"Barthel","year":"2011","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-230744_ref17","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.tips.2015.03.002","article-title":"Amyloid biomarkers in Alzheimer\u2019s disease","volume":"36","author":"Blennow","year":"2015","journal-title":"Trends Pharmacol Sci"},{"key":"10.3233\/JAD-230744_ref18","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1212\/WNL.0000000000002081","article-title":"Use of amyloid-PET to determine cutpoints for CSF markers: A multicenter study","volume":"86","author":"Zwan","year":"2016","journal-title":"Neurology"},{"key":"10.3233\/JAD-230744_ref19","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13195-019-0532-x","article-title":"Discordant amyloid- PET and CSF biomarkers and its clinical consequences","volume":"11","author":"de Wilde","year":"2019","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-230744_ref20","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1212\/WNL.0000000000001991","article-title":"Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease","volume":"85","author":"Palmqvist","year":"2015","journal-title":"Neurology"},{"key":"10.3233\/JAD-230744_ref21","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.3233\/JAD-151180","article-title":"Clinical utility of amyloidPET imaging in the differential diagnosis of atypical dementias and its impact on caregivers","volume":"52","author":"Bensa\u00efdane","year":"2016","journal-title":"J AlzheimersDis"},{"key":"10.3233\/JAD-230744_ref22","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1093\/clinchem\/47.10.1776","article-title":"Tau and A\u03b242 in cerebrospinal fluid from healthy adults 21\u201393 years of age: Establishment of reference values","volume":"47","author":"Sj\u00f6gren","year":"2001","journal-title":"Clin Chem"},{"key":"10.3233\/JAD-230744_ref23","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s40336-015-0102-6","article-title":"Beta-amyloid imaging with florbetaben","volume":"3","author":"Sabri","year":"2015","journal-title":"Clin Transl Imaging"},{"key":"10.3233\/JAD-230744_ref24","unstructured":"European Medicines Agency. Neuraceq. Annex 1. Summary of product characteristics. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-Product_Information\/human002553\/WC500162592.pdf(accessed 8th April 2015)."},{"key":"10.3233\/JAD-230744_ref25","doi-asserted-by":"crossref","first-page":"118775","DOI":"10.1016\/j.neuroimage.2021.118775","article-title":"rPOP: Robust PET-only processing of community acquired heterogeneous amyloid-PET data","volume":"246","author":"Iaccarino","year":"2022","journal-title":"Neuroimage"},{"key":"10.3233\/JAD-230744_ref26","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1007\/s00259-017-3749-6","article-title":"18F-Florbetaben PET beta-amyloid binding expressed in Centiloids","volume":"44","author":"Rowe","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.3233\/JAD-230744_ref27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jalz.2014.07.003","article-title":"The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET","volume":"11","author":"Klunk","year":"2015","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-230744_ref28","doi-asserted-by":"crossref","first-page":"900","DOI":"10.2967\/jnumed.115.161927","article-title":"Impact of training method on the robustness of the visual assessment of 18Fflorbetaben PET scans: Results from a phase-3 study","volume":"57","author":"Seibyl","year":"2016","journal-title":"J Nucl Med"},{"key":"10.3233\/JAD-230744_ref29","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"\u201cMini-mental state\u201d. A practical method for grading the cognitivestate of patients for the clinician","volume":"12","author":"Folstein","year":"1975","journal-title":"J Psychiatr Res"},{"key":"10.3233\/JAD-230744_ref30","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1177\/1533317517722630","article-title":"The TMA-93: A new memory test for Alzheimer's disease in illiterate and less educated people","volume":"32","author":"Maillet","year":"2017","journal-title":"Am J Alzheimers Dis Other Demen"},{"key":"10.3233\/JAD-230744_ref31","doi-asserted-by":"crossref","first-page":"871","DOI":"10.3233\/JAD-191235","article-title":"Norms for testing visual binding using the Memory Associative Test (TMA-93) in older educationally-diverse adults","volume":"75","author":"Rodrigo-Herrero","year":"2020","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-230744_ref32","doi-asserted-by":"crossref","first-page":"431","DOI":"10.3233\/ADR-200215","article-title":"Reliability and feasibility of the Memory Associative Test TMA-93","volume":"4","author":"Franco-Mac\u00edas","year":"2020","journal-title":"J Alzheimers Dis Rep"},{"key":"10.3233\/JAD-230744_ref33","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3233\/JAD-210115","article-title":"TMA-93 validation by Alzheimer\u2019s disease biomarkers: A comparison with the Free and Cued Selective Reminding Test on a biobank sample","volume":"82","author":"Rodrigo-Herrero","year":"2021","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-230744_ref34","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1176\/ajp.139.9.1136","article-title":"The global deterioration scale for assessment of primary degenerative dementia","volume":"139","author":"Reisberg","year":"1982","journal-title":"Am J Psychiatry"},{"key":"10.3233\/JAD-230744_ref35","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.neurobiolaging.2019.02.020","article-title":"Amyloid PET and cognitive decline in cognitively normal individuals: The SCIENCe project","volume":"79","author":"Timmers","year":"2019","journal-title":"Neurobiol Aging"},{"key":"10.3233\/JAD-230744_ref36","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S1474-4422(03)00530-1","article-title":"CSF markers for incipient Alzheimer\u2019s disease","volume":"2","author":"Blennow","year":"2003","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-230744_ref37","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1093\/brain\/aww139","article-title":"The relationship between cerebrospinal fluid markers of Alzheimer pathology and positron emission tomography tau imaging","volume":"139","author":"Gordon","year":"2016","journal-title":"Brain"},{"key":"10.3233\/JAD-230744_ref38","doi-asserted-by":"crossref","first-page":"559","DOI":"10.3233\/JAD-190836","article-title":"Why is amyloid-\u03b2 PET requested after performing CSF biomarkers?","volume":"73","author":"Reimand","year":"2020","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-230744_ref39","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1007\/s00415-019-09315-y","article-title":"Amyloid PETs are commonly negative in suspected Alzheimer's disease with an increase in CSF phosphorylated-tau protein concentration but an A\u03b242 concentration in the very high range: A prospective study","volume":"266","author":"Manca","year":"2019","journal-title":"J Neurol"},{"key":"10.3233\/JAD-230744_ref40","doi-asserted-by":"crossref","first-page":"e045412","DOI":"10.1002\/alz.045412","article-title":"Tau-first subtype of Alzheimer\u2019s disease progression consistently identified through PET and CSF","volume":"16","author":"Aksman","year":"2020","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-230744_ref41","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1212\/01.wnl.0000436625.63650.27","article-title":"Reduced CSF p-Tau181 to tau ratio is a biomarker for FTLD-TDP","volume":"81","author":"Hu","year":"2013","journal-title":"Neurology"},{"key":"10.3233\/JAD-230744_ref42","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0197-4580(03)00086-1","article-title":"Nerocheumical diagnosis of Alzheimer\u2019s dementia by CSF A\u03b242, A\u03b242\/A\u03b240 ratio and total tau","volume":"25","author":"Lewczuk","year":"2004","journal-title":"Neurobiol Aging"},{"key":"10.3233\/JAD-230744_ref43","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/acn3.274","article-title":"CSF A\u03b242\/A\u03b240 and A\u03b242\/A\u03b238 ratios: Better diagnostic markers of Alzheimer disease","volume":"3","author":"Janelidze","year":"2016","journal-title":"Ann Clin Transl Neurol"},{"key":"10.3233\/JAD-230744_ref44","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1001\/jama.2015.4668","article-title":"Prevalence of cerebral amyloid pathology in persons without dementia: A metanalysis","volume":"313","author":"Jansen","year":"2015","journal-title":"JAMA"}],"container-title":["Journal of Alzheimer's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JAD-230744","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:09:02Z","timestamp":1777370942000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JAD-230744"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,2]]},"references-count":44,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.3233\/jad-230744","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,2]]}}}